FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition contains aleglitezar or its sodium salt in a dose of 0.01 to 0.9 mg.
EFFECT: pharmaceutical composition of aleglitezar is used for treating or preventing type II diabetes mellitus or cardiovascular diseases.
32 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TWO-LAYERED TABLET FOR PREVENTING CARDIOVASCULAR DISTURBANCES, DRUG AND METHOD FOR PREVENTING CARDIOVASCULAR DISTURBANCES, INCLUDING APOPLEXY AND PARALYSIS BY USING SAID TABLET | 2007 |
|
RU2445088C2 |
| PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2485951C2 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION | 2014 |
|
RU2682178C2 |
| GALENICAL PREPARATIONS OF ORGANIC COMPOUNDS | 2010 |
|
RU2535090C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| PHARMACEUTICAL COMPOSITIONS OF MONTELUCAST AND LEVOCETIRISINE | 2013 |
|
RU2677649C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| SOLID PHARMACEUTICAL PREPARATION, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2809722C1 |
| IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2465900C2 |
| DOSAGE FORMS FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE | 2008 |
|
RU2546521C2 |
